The pharmaceutical industry's concerns grow over the government's plan to reevaluate foreign drug price comparisons.

The government has established a policy to reduce domestic drug prices by comparing them to those in 'A8 countries (United States·Japan·Germany·France·Italy·Switzerland·Canada).' As the policy is set to be effective, the industry is busy estimating the scale of damage.

Companies are estimated to experience a 5-20% reduction in annual sales. Therefore, the pharmaceutical industry voices concern that a sales reduction and an operational profit reduction will result in bigger damage. There are concerns that the scale of damage this time will be more substantial than th